Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 16

Complete If Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GO	283	09/441,140		Solomon et al.	11-16-1999	
	242	60/168,594		Chalifour et al.	N/A	
	282	60/169,687		Chain	N/A	
	295	60/184,601		Holtzman et al.	N/A	
	299	60/186,295		Rasmussen et al.	N/A	
	296	60/254,465		Holtzman et al.	N/A	
	297	60/254,498		Holtzman et al.	N/A	
	300	2001/0018053	A1	McMichael	08-30-2001	
	267	6,294,171	B2	McMichael	09-25-2001	
	234	6,284,221	B1	Schenk, et al.	09-04-2001	
	230	6,262,335	B1	Hsiao et al.	07-17-2001	
	231	6,114,133		Seubert et al.	09-05-2000	
	196	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	221	5,989,566		Cobb et al.	11-23-1999	
	2	5,958,883		Snow	09-28-1999	
	3	5,955,317		Suzuki et al.	09-21-1999	
	4	5,955,079		Mond et al.	09-21-1999	
	5	5,877,399		Hsiao et al.	03-02-1999	
	6	5,869,093		Weiner et al.	02-09-1999	
	7	5,869,054		Weiner et al.	02-09-1999	
	8	5,854,204		Findeis et al.	12-29-1998	
	9	5,851,996		Kline	12-22-1998	
	10	5,849,298		Weiner et al.	12-15-1998	
	11	5,837,473		Maggio e al.	11-17-1998	
	12	5,786,180		Konig et al.	07-28-1998	
	207	5,780,587		Potter	07-14-1998	
	13	5,753,624		McMichael et al.	05-19-1998	
	14	5,750,349		Suzuki et al.	05-12-1998	
	197	5,744,366		Goldgaber et al.	04-28-1998	
	211	5,736,142		Sette et al.	04-07-1998	
	15	5,733,547		Weiner et al.	03-31-1998	
	16	5,688,651		Solomon	11-18-1997	
GO	17	5,679,348		Nesburn et al.	10-21-1997	

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

GB	18	5,645,820		Hafler et al.	07-08-1997	
	19	5,641,474		Hafler et al.	06-24-1997	
	20	5,641,473		Hafler et al.	06-24-1997	
	21	5,612,486		McConlogue et al.	03-18-1997	
	22	5,605,811		Seubert et al.	02-25-1997	
	23	5,585,100		Mond et al.	12-17-1996	
	24	5,571,500		Hafler et al.	11-05-1996	
	25	5,571,499		Hafler et al.	11-05-1996	
	175	5,441,870		Seubert, et al.	08-15-1995	
	26	5,434,170		Andrulis, Jr.	07-18-1995	
	27	5,387,742		Cordell	02-07-1995	
	181	5,270,165		Van Nostrand et al.	12-14-1993	
	284	5,231,170		Averback	1993-07-27	
	28	5,231,000		Majocha et al.	07-27-1993	
	29	5,220,013		Ponte et al.	06-15-1993	
	30	5,208,036		Eppstein et al.	05-04-1993	
	31	5,192,753		McGeer et al.	03-09-1993	
	32	5,187,153		Cordell et al.	02-16-1993	
	33	5,057,540		Kensil et al.	10-15-1991	
	198	5,004,697		Pardridge	04-0201991	
GB	34	4,666,829		Glenner et al.	05-19-1987	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
GB	35	EP	911 036	A2		04-28-1999		
	36	EP	868 918	A2		10-07-1998		
	37	EP	863 211	A1		09-09-1998		
	38	EP	845 270	A1		06-03-1998		
	39	EP	782 859	A1		07-09-1997		
	40	EP	683 234	A1		11-22-1995		
	41	EP	666 080	A1		08-09-1995		
	42	EP	852 962	B1		12-16-1998		
	43	EP	639 081	B1		11-03-1999		
	44	EP	613 007	A2		08-31-1994		
	45	EP	594 607	B1		08-27-1997		
	46	EP	561 087	B1		08-04-1999		
	47	EP	526 511	B1		05-28-1997		
GB	48	EP	506 785	B1		03-15-2000		

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v23

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

EPO	49	EP	451 700	A1		10-16-1991		
	50	EP	440 619	B1		01-24-1996		
	51	EP	359 783	B1		11-29-1995		
	52	EP	276 723	B1		12-08-1993		Yes
	187	EP	783 104	A1		07-09-1997		
	294	PCT	01/62801	A2		08-30-2001		
	301	PCT	01/62284	A2		03-01-2000		
	298	PCT	01/42306	A2		06-14-2001		
	243	PCT	01/39796	A2		06-07-2001		
	199	PCT	00/77178	A1		12-21-2000		
	240	PCT	00/43039	A1		07-27-2000		
	188	PCT	00/43049	A1		07-27-2000		
	53	PCT	99/60024	A1		11-25-1999		
	54	PCT	99/60021	A2		11-15-1999		
	55	PCT	99/58564	A1		11-18-1999		
	56	PCT	99/06066	A2		02-11-1999		
	57	PCT	99/27949	A1		06-10-1999		
	58	PCT	99/27944	A1		06-10-1999		
	59	PCT	99/27911	A1		06-10-1999		
	203	PCT	99/00150	A2		01-07-1999		
	60	PCT	98/44955	A1		10-15-1998		
	61	PCT	98/07850	A2		02-26-1998		
	202	PCT	97/21728	A1		06-19-1997		
	62	PCT	97/17613	A1		05-15-1997		
	63	PCT	96/39176	A1		12-12-1996		
	208	PCT	96/28471	A1		09-19-1996		
	64	PCT	96/25435	A1		08-22-1996		
	65	PCT	96/18900	A1		06-20-1996		
	66	PCT	95/31998	A1		11-30-1995		
	200	PCT	95/12815	A1		05-11-1995		
	67	PCT	95/11994	A1		05-04-1995		
	68	PCT	95/11311	A1		04-27-1995		
	227	PCT	95/11008	A2		04-27-1995		
	69	PCT	95/05853	A1		03-02-1995		
	70	PCT	95/04151	A2		02-09-1995		
	201	PCT	94/28412	A1		12-08-1994		
	71	PCT	94/03615	A1		02-17-1994		
	72	PCT	94/01772	A1		01-20-1994		
	73	PCT	93/21950	A1		11-11-1993		
	74	PCT	93/16724	A1		09-02-1993		
EPO	75	PCT	93/15760	A1		08-19-1993		

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v23

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

CW	76	PCT	93/14200	A1		07-22-1993		
	205	PCT	93/04194	A1		03-04-1993		
	77	PCT	93/02189	A1		02-04-1993		
	78	PCT	92/13069	A1		08-06-1992		
	79	PCT	92/06708	A1		04-30-1992		
	80	PCT	92/06187	A1		04-16-1992		
	81	PCT	91/19810	A1		12-26-1991		
	82	PCT	91/16819	A1		11-14-1991		
	83	PCT	91/12816	A1		09-05-1991		
	84	PCT	91/08760	A1		06-27-1991		
	85	PCT	90/12871	A1		11-01-1990		
	86	PCT	90/12870	A1		11-01-1990		
	87	PCT	89/01343	A1		02-23-1989		
	88	PCT	89/08242	A1		07-13-1989		
	89	PCT	89/08689	A1		07-27-1989		
	90	PCT	89/03687	A1		05-05-1989		
	91	PCT	88/10120	A1		12-29-1988		
✓	92	GB	2 220 211	A		01-04-1990		
CW	93	GB	2 335 192	A		09-15-1999		

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v23

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Guriq, Basi *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
EP	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995).	
	95	Associated Press, "Immune cells may promote Alzehimer's, a study finds," *The Boston Globe* (4/13/95).	
	176	BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000).	
	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J. Mol.Biol., 225(4): 1075-1093 (1992).	
	96	BAUER et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991).	
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," Eur. J. Immunol. 29:345-354 (1999).	
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992).	
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999).	
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," Biochem. Biophys. Res. Comm., 171(2):890-897 (1990).	
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," Neuron, 19: 939-945 (1997).	
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," Cur. Opin. Genet Develop., 3: 102-109 (1993).	
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993).	
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropharm., 15:414A-414B (1992).	
EP	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm, last updated May 18, 2002.	

Examiner Signature		Date Considered	12/17/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

Sheet 6 of 16

GN	102	CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993).	
	266	CHAPMAN, PAUL F., "Model behavior," Nature, 408:915-916 (2000).	
	~~222~~	~~Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)~~	
	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," Neuroscience Letters 125:223-226 (1991).	
	302	CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells," J. Biol. Chem., 274(45):32301-32308 (1999).	
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000).	
	286	CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994).	
	287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," Scand. J. Immunol., 38:177-182 (1993).	
	293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998).	
	214	DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA, 10.1073/pnas.151261398 (2001).	
	~~220~~	~~Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. - comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water-sol. organic solvent and saline or water. Derwent File 351: Derwent WPI database. (Publication date unknown.)~~	
	103	DUFF et al., "Mouse model made," Nature, 373: 476-477 (1995).	
	288	DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-85 (2001).	
	225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).	
	226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)	
↓	104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," J. Neurol. Sciences, 59:341-347 (1983).	
GN	289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends in Pharm. Sci., 22:2-3 (2001).	

(222 & 220 NOT PRINTED; CONSIDERED) GN 12/27/04

Examiner Signature	G Nichols	Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

PA 3147648 v23

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

GD	105	FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993).	
	106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996).	
	107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991).	
	108	FLANDERS et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995).	
	246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001).	
	247	FRENKEL et al., "Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000).	
	248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neuroimmunology, 88:85-90 (1998).	
	245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999).	
	244	FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 106:23-31 (2000).	
	210	FRIEDLAND et al., ""Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," Mol. Neurology, 9:107-113 (1994).	
	249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	
	109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," Nature, 373(6514): 523-527 (1995).	
	215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with $A\beta_{1-42}$," Annals of the New York Academy of Science 920:274-84 (2000).	
	110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," TiPS, 13:108-113 (1992).	
	251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem. Biophys. Res. Comm., 173:1292-1298 (1990).	
	111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," J. Exp. Med., 177:1181-1188 (1993).	
✓	252	GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," Neurobiology of Aging, 20:75-79 (1999).	
GD	253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," Journal of Biological Chem., 273:29719-29726 (1998).	

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 16

Complete If Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

	112	GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998).	
	114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," Biochemical and Biophysical Research Communications, 122(3): 1131-1135 (1984).	
	113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochemical and Biophysical Research Communications, 120(3): 885-890 (1984).	
	115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991).	
	303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," Immunology, 93:149-153 (1998).	
	237	GORTNER, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949).	
	116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS USA, 93:427-432 (1996).	
	190	GRAVINA et al., "Amyloid β Protein (Aβ) in Alzheimer's Disease," J. Biol. Chem., 270(13):7013-7016 (1995).	
	254	GRUBECK-LOEBENSTEIN, et al., "Immunization with β-amyloid: could T-cell activation have a harmful effect?", TINS, 23:114 (2000).	
	117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," Vaccine, 15(12/13): 1341-1343 (1997).	
	241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992).	
	118	HAGA et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601:88-94 (1993).	
	182	HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996).	
	119	HANES et al., "New advances in microsphere-based single-dose vaccines," Advanced Drug Delivery Reviews, 28: 97-119 (1997).	
	120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," TINS, 20(4): 154-159 (1997).	
	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1996).	
	255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," Biochem. Biophys. Res. Comm., 211:1015-1022 (1995).	
	193	HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," Biochimica Biophysica Acta, 1158:120-128 (1993).	

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v23

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE OCT 0 7 2002 PATENT & TRADEMARK OFFICE

RECEIVED OCT 15 2002

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 16

Complete If Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

GN	229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993).	
	177	HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," Science, 289:375 (2000).	
	236	HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4," Eur. J. Biochem., 201:61-69 (1991).	
	122	HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice," Science, 274: 99-102 (1996).	
	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994).	
	~~174~~	~~Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).~~	
	124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).	
	256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," Lab. Invest., 57:446-449 (1987).	
	125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," J. Neuroimmunology, 24:173-182 (1989).	
	192	IWATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," Neuron, 13:45-53 (1994).	
	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62: 185-216 (1982).	
	257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997).	
	216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am. J. of Pathology 138:373-384 (1991).	
	127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992).	
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," Biotechnol. Appl. Biochem., 23:227-230 (1996).	
	128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991).	
	258	KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995).	
GN	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the βA4 Peptide," Annals of NY Acad. Sci., 777:344-355 (1996).	

(3412002) IDS # 12 PAPER NO. 12 (20051220)

Examiner Signature	G Nichols	Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

PA 3147648 v23

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 16

Complete If Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

	129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993).	
	130	LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990).	
	131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res., 57:207-213 (1993).	
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," Curr. Ops. in Chemical Biology, 1:260-267 (1997).	
	132	LEMERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden in Pd-App Transgenic Mice," Society for Neuroscience Abstracts, vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).	
	260	LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," Annals of the NY Acad. Sci., 920:328-331 (2000).	
	184	LI and SOLOMON, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," Biochem. Mol. Biol. Int., 43(3):601-611 (1997).	
	133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997).	
	134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," Acta. Neurol. Scand., 84:441-444 (1991).	
	218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992).	
	261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," Brain Research, 667:138-142 (1994).	
	263	MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $A\beta_{42(43)}$," Annals of Neurology, 40:149-156 (1996).	
	262	MANN; et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995).	
	217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985).	
	135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997).	
	264	McGeer, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," J. of Neuroscience Res., 31:428-442 (1992).	
	238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," Virology, 243:158-166 (1998).	
	136	MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995).	

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~4645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

GW	265	Mena, et al., "Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995).
	137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991).
	206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992).
	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989).
	191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).
	250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. Anim., 43:711-718 (1995).
	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43)) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995).
	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," J. of Med. Primatology, 27:244-252 (1998).
	138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," Am. J. Epidemiol., 145(11): 959-969 (June 1, 1997).
	139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).
	235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," Biochim. Biophys. Acta, 104:480-486 (1965).
	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Biochem. Biophys. Res. Comm., 146:307-313 (1987).
	140	PARESCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996).
	141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," Eur. J. Immunol., 25: 3521-3524 (1995).
	232	PETERSON, et al., " Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," Laboratory Animal Science, 46(1):8-14 (1996).
	269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," J. of Neuroscience Res., 46:709-719 (1996).
✓	142	PRIEELS et al., "Synergistic adjuvants for vaccines," Chemical Abstracts, 120(8): pg. 652, column 1, abstract 86406t (1994).
GW	143	QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991).

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v23

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OIPE OCT 07 2002 PATENT & TRADEMARK OFFICE

RECEIVED OCT 15 2002 TECH CENTER 1600/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

GN	145	RASO, "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly, Abstract (April 2, 1998).	
	~~144~~	~~RASO, V.A., Grant application # 1 R43 AGI 5746-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).~~	
	~~304~~	~~RASO, V.A., Grant application # 1 R43 AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).~~	
	146	ROGERS et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992).	
	147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993).	
	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	
	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 268(33):25239-25243 (1993).	
	194	SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," J. Biol. Chem., 269(21):15253-15257 (1994).	
	279	SAITO et al., "Vector-mediated delivery of ^{125}I-labeled β-amyloid peptide Ab$^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ$^{1-40}$ vector complex," PNAS USA, 92:10227-10231 (1995).	
	278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti-β-protein monoclonal antibodies," Sapporo Med. J., 60:309-320 (1991).	
	277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," Brain Res., 755:193-201 (1997).	
	148	SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999).	
	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1995).	
	270	SCHENK, et al., "β-peptide immunization," Arch. Nuerol., 57:934-936 (2000).	
	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994).	
	151	SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," Trends in Neurosciences, 16(10): 403-409 (1993).	
	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000).	
GN	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997).	

404# 144# 1N2K 204 0d (A22262506)

Examiner Signature	G Nichols	Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v23

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	13	of	16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

GN	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease……," Scientific American, pgs. 68-78 (November, 1991).	
	153	SELKOE, Dennis J., "In the Beginning…," Nature, 354:432-433 (1991).	
	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991).	
	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," Nature, 359: 325-327 (1992).	
	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992).	
	158	SMITS et al., "Prion Protein and Scrapie Susceptibility," Vet. Quart., 19(3): 101-105 (1997).	
	185	SOLOMON and GOLDSTEIN, "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996).	
	~~186~~	~~SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).~~	
	159	SOLOMON et al., "Disaggregation of Alzheimer β-amyloid by site-directed mAb," PNAS USA, 94:4109-4112 (1997).	
	160	SOLOMON et al., "Monoclonal antibodies inhibit in *vitro* fibrillar aggregation of the Alzheimer β-amyloid peptide," PNAS USA, 93:452-455 (1996).	
	~~161~~	~~SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).~~	
	~~162~~	~~SOLOMON, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown).~~	
	179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996).	
	271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116-117 (1999).	
	163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against *Plasmodium Falciparum* Malaria", N. Engl. J. Med., 336(2): 86-91 (1997).	
	164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," PNAS, 94: 13287-13292 (1997).	
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on *in vitro* properties of the amyloid β-peptide as modeled with *N*-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-298 (1996).	
GN	165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998).	

Examiner Signature	[signature]	Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

PA 3147648 v23

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 16

Complete If Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

CD	273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," Curr. Op. in Chem. Biology, 4:377-382 (2000).	
	276	TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, 271:8545-8548 (1996).	
	166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994).	
	167	VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994).	
	168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994).	
	169	WALKER et al., "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994).	
	274	WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000).	
	171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).	
	172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. Opin. Neurobiol., 7: 695-700 (1997).	
	180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998).	
	170	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Biotech., 18:868-872 (2000).	
	~~223~~	~~Wisconsin Alumni Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)~~	
	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," PNAS USA, 82:8729-8732 (1985).	
	173	WOOD et al., "Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease," PNAS USA, 94: 1550-1555 (1997).	
	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997).	
↓	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998).	
CD	290	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	

DO NOT PRINT # 223 / DISCARD

Examiner Signature		Date Considered	12/27/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

	A1	Chen G, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000 Dec 21-28;408(6815):975-9
	A2	Janus C, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000 Dec 21-28;408(6815):979-82
	A3	Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997 Oct;77(4):1081-132
	A4	Merluzzi S, et al. Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path. 2000 Apr;4(2):77-85.
	A5	Morgan D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000 Dec 21-28;408(6815):982-5
	A6	Schenk D, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 2001 Nov;20(11):679-81
	A7	Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998 Nov;8(11):447-53
	A8	Sigurdsson EM, et al. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 2000 Jan;59(1):11-17
	A9	Sinha S, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 2000;920:206-8
	A10	Soto C, et al. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 1998 Jul;4(7):822-6
	A11	Vehmas AK, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. DNA Cell Biol. 2001 Nov;20(11):713-21

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A12	5,593,846		Schenk et al.	01-14-1997	
	A13	5,837,672		Schenk et al.	11-17-1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A14		WO 00/72876	A2, A3		12-07-2000		
	A15		WO 00/72880	A2, A3		12-07-2000		

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 16 of 16

Complete if Known	
Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq *et al.*
Group Art Unit	~~1645~~ 1647
Examiner Name	Nichols
Attorney Docket Number	ELN-002

CEP	B1	Du Y, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001 Sep 11;57(5):801-5.	1
CEP	B2	Small DH, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2001 Aug;2(8):595-8	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CEP	B3	US 2001/0102261	A1	Raso	08-01-2002	
CEP	B4	US 2002/0136718	A1	Raso	09-26-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CEP	B5		WO 00/77178	A1		12-21-2000		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CEP	B6	09/724,842		Chalifour et al.	~~N/A~~	

Examiner Signature		Date Considered	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		ELN-002	10/010942
		APPLICANT: Basi, Guriq *et al.*	
		FILING DATE: December 6, 2001	GROUP: ~~1645~~ 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	B1	JP 7-165799	06/95	Japan			Abstract Only	
	B2	WO 00/23082 A1	04/00	WO				
	B3	WO 00/72880 A2,A3	05/00	WO				
	B4	WO 02/088306 A2	11/02	WO				
	B5	WO 02/088307 A2	11/02	WO				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	B6		Bard, F. *et al.* "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," *Nature Medicine* 6(8):916-919 (Aug 2000).
	B7		Kettleborough, C.A. *et al.* "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," *Protein Engineering* 4(7):773-783 (1991).

Examiner	Date Considered
	12/27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	306	6,417,178 B1	07-09-2002	Klunk, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	324	WO 00/72870 A1	12-07-2000	Neuralab Ltd.		
	331	WO 99/06545	11-02-1999	Max Planck Gesellschaft		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	327	Cameron. "Recent Advances in Transgenic Technology," *Molecular Biotechnology*. 1997; 7:253-65.	
	328	Feldstein, *et al.* "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing." *Alzheimer's and Parkinson's Diseases*. 1995; Hanin, *et al.* Ed., pp 401-9, Plenum Press, New York.	
	329	Niemann. "Transgenic farm animals get off the ground." *Transgenic Research*. 1998; 7:73-5.	
	330	Sigmund. "Viewpoint: Are Studies in Genetically Altered Mice Out of Control." *Arterioscler Thromb Vasc Biol*. 2000; 20:1425-9.	
	332	Chen, *et al.* "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice." *Progress in Brain Research*. Van Leeuwen, *et al.* Eds, 1998; 117:327-37.	
	333	Conway, *et al.* "Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy." *PNAS.*, 2000; 97(2):571-6.	
	334	Jobling and Holmes, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis." *Molecular Microbiology*. 1991; 5(7):1755-67.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CJN	340	2002/0162129 A1	10-31-2002	Lannfelt	
	342	2002/0009445 A1	01-24-2002	Du, *et al.*	
	345	2002/0077288 A1	06-21-2001	Frangione	
CJN	346	5,935,927	08-10-1999	Vitek, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CJN	341	WO 02/03911 A2	01-17-2002	Lannfelt, L.		
CJN	343	EP 1172378 A1	01-16-2002	Dodel, Dr. R., *et al.*		
CJN	344	WO 01/90182 A2	11-29-2001	University of New York		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	335	Masliah, *et al.* "β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease." *PNAS.* 2001; 98(21):12245-50.	
	336	Perutz, *et al.* "Amyloid fibers are water-filed nanotubes." *PNAS.* 2002; 99(8):5591-5.	
	337	Skolnick and Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era." *Trends in Biotech.* 2000; 18(1):34-9.	
	338	Stein, *et al.* "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways." *The Journal of Neuroscience.* 2002 Sep 1; 22(17):7380-8.	
CJN	339	Tennent, *et al.* "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis." *PNAS.* 1995; 92:4299-303.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GW	353	5,824,322	10-20-1998	Balasubramanian	
	356	5,622,701	04-22-1997	Berg	
	357	5,776,468 B1	07-07-1998	Hauser, *et al.*	
GW	358	5,583,112 B2	12-10-1996	Kensil, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
GW	348	WO 01/77167 A2	10-18-2001	Univ Tennessee Res Corp		
GW	351	WO 02/34878 A2	05-02-2002	Yeda Resrstvh & Development Co. Ltd.		
GW	352	WO 02/34777 A1	05-02-2002	Chiesi Farma SPA		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GW	347	Jorbeck, *et al.* "Artificial *Salmonella* Vaccines: *Salmonella typhimurium* O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis." *Infection and Immunity*. 1981 May; 497-502.	
	349	Check. "Battle of the Mind." *Nature*. 2002 Mar; 422:370-2.	
	350	Nicoll, *et al.* "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report." *Nature Medicine*. 2003 Apr; 9(4):448-52.	
	354	Mutschler, *et al.* "Drug Actions: Basic Principles and Therapeutic Aspects." 1995; 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.	
	355	Munson ed. "Principals of Pharmacology: Basic Concepts & Clinical Applications." 1995; 47-8, Chapman & Hall, New York, New York.	
GW	359	Munch, *et al.* "Potentional neurotoxic inflammatory response to Aβ vaccination in humans" *J. Neural Transm.* 2002; 109:1081-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GSD	360	2003/0073655 A1	04-17-2003	Chain	
	362	2002/0094335 A1	07-18-2002	Chalifour, *et al.*	
	365	2002/0133001 A1	09-19-2002	Gefter, *et al.*	
	366	2002/0187157 A1	12-12-2002	Jensen, *et al.*	
GSD	370	2003/0068325 A1	04-10-2003	Wang	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GSD	361	Su, *et al.* "Intravascular infusions of soluble β-amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage." *Brain Research.* 1999; 818:105-7.	
	363	Dodart. "Immunotherapy for Alzheimer's disease: will vaccination work?" *Trends in Molecular Medicine.* 2003; 9(3):85-7.	
	364	Furlan, *et al.* "Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice." *Brain.* 2003; 126:285-91.	
	367	Monsonego, *et al.* "Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease." *PNAS.* 2001; 98(18):10273-8.	
	368	Sipe. "Amyloidosis." *Annu. Rev. Biochem.* 1992; 61:947-75.	
GSD	369	Spooner, *et al.* "The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol." *Vaccine.* 2002; 21:290-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GJB	373	5,721,130	02-24-1998	Seubert, *et al.*	
	376	2002/0086847 A1	07-04-2002	Chain	
	377	2002/0168377 A1	11-14-2002	Schaetzl	
	378	2002/0197258 A1	12-26-2003	Ghanbari, *et al.*	
	379	2002/0132268 A1	09-19-2002	Chang, *et al.*	
	380	5,750,361	05-12-1998	Prusiner, *et al.*	
GJB	381	2001/0021769 A1	09-13-2001	Prusiner	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GJB	371	Johnstone, *et al.* "Nuclear and Cytoplasmic Localization of the β-Amyloid Peptide (1-43) in Transfected 293 Cells." *Biochemical and Biophysical Research Communications*. 1996; 220:710-18.	
	372	Akiyama, *et al.* "Occurrence of the Diffuse Amyloid β-Protein (Aβ) Deposits With Numerous Aβ-Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease." *Glia*. 1999; 25:324-31.	
	374	Jakes, *et al.* "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease." *Alzheimer Disease and Associated Disorders*. 1995; 9(1):47-51, Raven Press, Ltd., New York.	
GJB	375	Tsuzuki, *et al.* "Amyloid β protein in rat soleus in choroquine-induced myopthy using end-specific antibodies for Aβ40 and Aβ42: immunohistochemical evidence for amyloid β protein." *Neuroscience Letters*. 1995; 2002:77-80.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CJN	382	5,846,533	12-08-1998	Prusiner	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CJN	383	WO 97/10505 A1	03-20-1997	University of California		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	384	Sigurdsson, *et al.* "Immunization Delays the Onset of Prion Disease in Mice." *American Journal of Pathology*. 2002; 161:13-17.	
	385	Wisniewski, *et al.* "Therapeutics in Alzheimer's and Prion Diseases." *Biochemical Society Transactions*. 2002; 30(4):-574-87.	
	386	Frautschy, *et al.* "Effects of injected Alzheimer β-amyloid cores in rat brain." *PNAS*. 1991; 88:8362-6.	
	387	Weldon, *et al.* "Neurotoxicity of Aβ Peptide: Confocal Imaging of Cellular Changes Induced by –Amyloid in Rat CNS *In Vivo*." *Society for Neuroscicence Abstracts*. 1996; 22(Part 1).	
	388	Goldfarb, *et al.* "The Transmissible Spongiform Encephalopathies." *Ann. Rev. Med.* 1995; 46:57-65.	
	389	Kovacs, *et al.* "Mutations of the Prion Protein Gene Phenotypic Spectrum." *J. Neurol.* 2002; 249:1567-82.	
	390	Diomede, *et al.* "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes." *Biochem. J.* 1996; 320:563-70.	
	391	Aguzzi, *et al.* "Prion research: the next frontiers." *Nature*. 1997; 389:795-8.	
CJN	392	Tal, *et al.* "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice." *Journal of Neuroscience Research*. 2003; 71:286-90.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GSP	395	2002/0160394 A1	10-31-2002	Wu	
	401	6,284,533 B1	09-04-2001	Thomas	
	402	4,713,366	12-15-1987	Stevens	
GW	403	5,464,823	11-07-1995	Lehrer, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GW	393	Akiyama, *et al.* "Inflammation and Alzheimer's disease." *Neurobiology of Aging.* 2000; 21:383-421.	
	394	Prusiner, *et al.* "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies." *PNAS.* 1993; 90:10608-12.	
	396	Sigurdsson, *et al.* "Anti-priori antibodies for prophylaxis following prion exposure in mice." *Neurosciences Letters.* 2003; 336:185-7.	
	397	Goldsteins, *et al.* "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants." *PNAS.* 1999; 96:3108-13.	
	398	Palha, *et al.* "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy." *J. Mol. Med.* 2001; 7:703-7.	
	399	Tan, *et al.* " Amyloidosis." *Histopathology.* 1994; 25:403-14.	
	400	Sigurdsson, *et al.* "A safer vaccine for Alzheimer's disease?" *Neurobiology of Aging.* 2002; 23:1001-8.	
GW	404	Benjamini and Leskowitz, from *IMMUNOLOGY A Short Course*, Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	405	6,399,314 B1	06-04-2002	Krishnamurthy	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	406	Pan, *et al.* "Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide." *Exp. Biol. Med.* 2002; 227(8):609-15.	
	407	Eck, *et al. Goodman and Gilman's The pharmacological basis of therapeutics*, 1996; Chapter 5, pages 77-101.	
	408	Marshall. "Gene Therapy's Growing Pains." *Science.* 1995; 269:1050-55.	
	409	Orkin, *et al. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy*, December 7, 1995.	
	410	Verma, *et al.* "Gene therapy - promises, problems and prospects." *Nature.* 1997; 389:239-42.	
	411	Solomon, *et al.* "The Amino Terminus of the β-Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility" from *Progress in Alzheimer's and Parkinson's Diseases*, edited by Fisher et al., Plenum Press, New York, pages 205-11 (1995).	
	412	Das, *et al.* "Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ Knock-Out-Mice." *J. Neuroscience.* 2003; 23(24):8532-8.	
	413	Holtzman, *et al.* "Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer's disease." *Advanced Drug Delivery Reviews.* 2002; 54:1603-13.	
	414	Schenk. "Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning." *Nature Reviews.* 2002; 3:824-8.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CSD	415	2003/0166558 A1	09-04-2003	Frangione, *et al.*	
CSD	416	6,303,567 B1	10-16-2001	Findeis, *et al.*	
CSD	417	5,985,242	11-16-1999	Findeis, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CSD	418	Bork. "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle." *Genome Research*. 2000; 10:398-400.	
	419	Bork, *et al.* "Go hunting in sequence databases but watch out for the traps." *Trends in Genetics*. 1996; 12(10):425-7.	
	420	Brenner. "Errors in genome annotation." *Trends in Genetics*. 1999; 15(4):132-3.	
	421	Castillo, *et al.* "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology." *Diabete & Metabolisme (Paris)*. 1995; 21:3-25.	
	422	Doerks, *et al.* "Protein annotation: detective work for function prediction." *Trends in Genetics*. 1998; 14(6):248-50.	
	423	Fonseca, *et al.* "The Presence of Isoaspartic Acid in β-Amyloid Plaques Indicates Plaque Age." *Experimental Neurology*. 1999; 157(2):277-88.	
✓	424	Goldsby, *et al.* "Vaccines," Chapter 18 from *Immunology, 4th Edition*, W.H. Freeman and Company, New York, pages 449-465. (2002)	
CSD	425	Ngo, *et al.* "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of *The Protein Folding Problem and Tertiary Structure Prediction*, Merz et al., eds., Birkhauser Boston (1994).	

12/13/04 CSD

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/3/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GD	431	2003/0165496 A1	09-04-2003	Basi, *et al.*	
GD	432	6,562,341 B2	05-13-2003	Prusiner, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
GD	433	WO 03/020212	03-13-2003	Mayo Foundation for Medical Education and Research		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GD	426	Singh, K.S. "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease." *Gerontology*. 1997; 43:79-94.	
	427	Smith, *et al.* "The challenges of genome sequence annotation or 'The devil is in the details." *Nature Biotechnology*. 1997; 15:1222-3.	
	428	Velazquez, *et al.* "Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis." *Nature Medicine*. 1997; 3(1):77-9.	
	429	Wells. "Additivity of Mutational Effects in Proteins." *Biochemistry*. 1990; 29(37):8509-17.	
	430	Yang, *et al.* "Effects of Racemization on the Aggregational Properties of the Amyloid β-Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	
	434	Kelly. "Alternative conformations of amyloidogenic proteins govern their behavior." *Current Opinion in Structural Biology*. 1996; 6:11-17.	
GD	435	Stern, *et al.* "Antibodies to the β-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood." *FEBS Letters*. 1990; 264(1):43-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GW	440	2003/0068316 A1	04-10-2003	Klein, *et al.*	
	442	6,713,450 B2	03-30-2004	Frangione, *et al.*	
	444	2004/0043418 A1	03-04-2004	Holtzman, *et al.*	
	445	5,854,215	12-29-1998	Findeis, *et al.*	
GW	446	5,817,626	10-06-1998	Findeis, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
GW	441	WO 03/104437 A2	12-18-2003	Northwestern University		
GW	443	WO 03/074081 A1	09-12-2003	Mindset Biopharmaceuticals USA		
GW	447	WO 03/051374 A2	06-26-2003	New York State Office of MENTA		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GW	436	Dickson, *et al.* "Neuroimmunology of Alzheimer's disease: a conference report." *Neurobiology of Aging.* 1992; 13(6):793-8, abstract only.	
	437	Persson, *et al.* "IgG subclass-associated affinity differences of specific antibodies in humans." *J. Immunology.* 1988; 140(11):3875-9, abstract only.	
	438	Singh, V.K. "Studies of neuroimmune markers in Alzheimer's disease." *Mol. Neurobiology.* 1994; 9(1-3):73-81, abstract only.	
	439	Nalbantoglu. "Beta-amyloid protein in Alzheimer's disease." *Can. J. Neurol. Sci.* 1991; 18(3 suppl.):424-7, abstract only.	
GW	448	Andrew, *et al. Current Protocols in Immunology.* 1997; 2.7.1-2.9.8.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CJN	451	5,766,846	06-16-1998	Schlossmacher, *et al.*	
CJN	452	6,218,506 B1	04-17-2001	Krafft, *et al.*	
CJN	453	2002/0058267 A1	05-16-2002	Ozenberger, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CJN	450	WO 01/18169 A3	03-15-2001	Ramot University		
	454	WO 98/33815 A1	08-06-1998	Acumen Pharmaceuticals, Inc.		
	455	WO 01/10900 A2	02-15-2001	University of Southern California, *et al.*		
	456	WO 02/021141 A2	03-14-2002	Aventis Pharma SA, *et al.*		
	457	WO 02/406237 A1	06-13-2002	Neuralab Ltd., *et al.*		
CJN	458	WO 02/060481 A1	08-08-2002	Milkhaus Lab, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	449	Johnson-Wood, *et al.* "Amyloid precursor protein processing and $A\beta_{42}$ deposition in a transgenic mouse model of Alzheimer disease." *PNAS.* 1997; 94:1550-5.	
	459	Levitt. "Molecular dynamics of native protein." *J. Mol Biol.* 1983; 168:595-620.	
	460	Queen, *et al.* "A humanized antibody that binds to the interleukin 2 receptor." *Proc Nalt Acad Sci USA.* 1989; 86:10029-33.	
	461	Burdick, *et al.* "Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide antigens." *J Biol Chme.* 1992; 267:546-55.	
CJN	462	Co, *et al.* "Chimeric and humanized antibodies with specificity for the CD33 antigen." *J Immunol.* 1992; 148:1149-54.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	463	Ghiso, *et al.* "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease." *Biochem J.* 1992; 282 (Pt 2):517-22.	
	464	Flood, *et al.* "An amyloid β-Protein fragment, A β [12-28J, equipotently impairs post-training memory processing when injected into different limbic system structures." *Brain Res.* 1994; 663(2):271-6.	
	465	Koudinov, *et al.* "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma." *Biochem & Biophysic Res Comm.* 1994; 205:1164-71.	
	466	Schwarzman, *et al.* "Transthyretin sequesters amyloid β protein and prevents amyloid formation." *Proc Natl Acad Sci.* 1994; 91:8368-72.	
	467	Tabaton, *et al.* "Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid." *Biochem and Biophysi Res Comm.* 1994; 200(3):1598-1603.	
	468	Wisniewski, *et al.* "Alzheimer's disease and soluble A beta." *Neurobiol Aging.* 1994; 15(2):143-52, Review.	
CJN	469	DeMattos, *et al.* "Peripheral anti-Aβ antibody alters CNS and plasma clearance and decreases Aβ burden in a mouse model of Alzheimer's ~~disease3.~~" *Proc Natl Acad Sci USA.* 98(15):8850-55. (17 July 2001) disease	

12/13/04 CJN

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	470	Giulian, *et al.* "Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia." *J Neurosci.* 1996; 16 (19):6021-37.	
	471	Hilbich, *et al.* "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease βA4 peptides." *J. Mol. Biol.* 1992; 228:460-73.	
	472	Teller, *et al.* "Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome." *Nature Medicine.* ~~1998~~ 2(1):93-95. (1996)	
	473	Hilbich, *et al.* "Aggregation and secondary structure of synthetic amylold βA4 peptides of Alzheimer's disease." *J. Mol. Biol.* 1991; 218:149-63.	
	474	Winter, *et al.* "Humanized antibodies." *Immunology Today.* 1996; 14(6):243-6.	
	475	El-Agnaf, *et al.* "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide." *Eur J Biochem.* 1998; 256(3):560-9.	
	476	He, *et al.* "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin." *J Immunol.* 1998; 160:1029-35.	
	477	Lambert, *et al.* "Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins." *Proc Natl Acad Sci.* 1998; 95:6448-53.	
CJN	478	Kuo, *et al.* "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease." *Biochem Biophys Res Commun.* 1999; 257(3):787- 91.	

12/13/04 CJN

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 15 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	479	McLean, *et al.* "Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease." *Amer Neurological Assoc.* 1999; 46:860-6.	
	480	Wang, *et al.* "The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging." *Experimental Neurology.* 1999; 158:328-37.	
	481	Levy, *et al.* "Immunization for Alzheimer's disease: A shot in the arm or a whiff?" *American Neurological Assoc.* 2000; 48:553-4.	
	482	Naslund, *et al.* "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline." *J Am Med Assoc.* 2000; 283:1571.	
	483	Zlokovic, *et al.* "Clearance of amyloid β-peptide from brain: transport or metabolism?" *Nature Medicine.* 2000; 6(7):718-19.	
	484	Arendiash, *et al.* "Behavioral assessment of Alzheimer's transgenic mice following long-term Aβ vaccination: Task specificity and correlations between Aβ deposition and spatial memory." *DNA and Cell Biology.* 2001; 20(11):737-44.	
	485	Bacskai, *et al.* "Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy." *Nature Medicine.* 2001; 7(3): 369-72.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 16 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	486	Dickey, *et al.* "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β-amyloid 1-42 peptide." *DNA and Cell Biology*. 2001; 20(11):723-9.	
	487	Haass, *et al.* "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?" *Nature Neuroscience*. 2001; 4(9):859-60.	
	488	Klein, *et al.* "Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?" *Trends in Neurosciences*. 2001; 24(4):219-24.	
	489	Lambert, *et al.* "Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies." *J Neurochem*. 2001; 79:595-605.	
	490	Lee, *et al.* "Aβ immunization: Moving Aβ peptide from brain to blood." PNAS. 2001; 98(16): 8931-2.	
	491	Poduslo, *et al.* "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease." *Neurobiol Dis*. 2001; 8(4): 555-67.	
	492	Town, *et al.* "Characterization of murine immunoglobulin G antibodies against human amyloid-β_{1-42}." *Neurosci Lett*. 2001; 307:101-4.	
CJN	493	DeMattos, *et al.* "Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease." *J Neurochem*. 2002; 81:229-36.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 17 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GW	494	Kotilinek, *et al.* "Reversible memory loss in a mouse transgenic model of Alzheimer's disease." *J Neurosci.* 2002; 22(15):6331-5.	
	495	Wang, *et al.* "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rate dentate gyrus." *Brain Research.* 2002; 924:133-40.	
	496	Strbak, *et al.* "Passive Immunization and Hypothalamic Peptide Secretion." *Neuroendocrinology.* 1993; 58:210-17.	
	497	Ragusi, *et al.* "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies." *J. Neurochem.* 1998; 70(5):2099-105.	
	498	Suo, *et al.* "Soluble Alzhelmers β-amyloid constricts the cerebral vasculature in vivo." *Neuroscience Letters.* 1998; 257:77-80.	
	499	Lue, *et al.* "Soluble β-amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease." *Am. J. Pathol.* 1999; 155:853-62.	
	500	Tjemberg, *et al.* "A molecular model for Alzheimer amyloid β-peptide fibril formation." *J. Biol. Chem.* 1999; 274(18):12619-25.	
GW	501	Esler, *et al.* "Point substitution in the central hydrophobic cluster of a human β-amyloid congener disrupts peptide folding and abolishes plaque competence." *Biochemistry/* 1996; 35:13914-21.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 18 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
EGD	502	Maggio, *et al.* "Brain Amyloid - A Physicochemical Perspective." *Brain Pathology*. 1996; 6:147-62.	
	503	Gorevic, *et al.* "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern." *Biochem. and Biophy. Res. Commun.* 1987; 147(2).	
	504	Balbach, *et al.* "Amyloid fibril formation by $A\beta_{16-22}$, a seven-residue fragment of the Alzheimer's β-amyloid peptide, and structural characterization by solid state NMR." *Biochemistry*. 2000; 39:13748-59.	
	505	Simmons. "Secondary structure of amyloid β peptide correlates with neurotoxic activity *in vitro*." *Molecular Pharmacology*. 1994; 45:373-9.	
	506	Wood, *et al.* "Prolines and amyloidogenicily in fragments of the Alzheimer's peptide β/A4." *Biochemistry*. 1995; 34:724-30.	
	507	Xu, *et al.* "Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease." *Mechanisms of Aging and Development*. 1997; 94:213-22.	
EGD	508	Soto, *et al.* "The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation." *J. Biol. Chem.* 1995; 270(7):3063-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 19 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GP	510	6,022,859	02-08-2000	Kiessling, *et al.*	
	511	6,331,440	12-18-2001	Nordstedt, *et al.*	
	512	5,891,991	04-06-1999	Wasco, *et al.*	
	513	5,514,548	05-07-1996	Krebber, *et al.*	
	514	5,470,951	11-28-1995	Roberts	
	515	5,652,334	07-29-1997	Roberts	
GP	516	6,261,569	07-17-2001	Comis, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
GP	517	WO 94/05311 A1	03-17-1994	Deakin Research Ltd.		
	518	WO 95/23166 A1	08-31-1995	Deakin Research Ltd.		
	519	WO 00/26238 A2	05-11-2000	Imperial College Innovations Ltd.		
	520	WO 98/22120 A1	05-28-1998	University of Pennsylvania, *et al.*		
	521	WO 98/05350 A1	02-12-1998	Milkhaus Lab, Inc.		
	522	WO 00/20027 A2	04-13-2000	M&E Biotech AS		
	523	EP 752886 B1	01-28-1998	Mouritsen & Elsner AS		
	524	WO 95/05393 A2	02-23-1995	Morphosys Proteinoptimierung		
GP	525	WO 98/02462 A1	01-22-1998	Morphosys Proteinoptimierung		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GP	509	Cirrito, *et al.* "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details." *J. Clin. Invest.* 2003; 112:321-3.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 20 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CJN	526	WO 99/06587 A2	02-11-1999	Morphosys AG		
	527	WO 97/32017 A1	09-04-1997	Morphosys Proteinoptimierung		
	528	WO 97/08320 A1	03-06-1997	Morphosys AG		
	529	WO 00/68263 A2	11-16-2000	Neurochem, Inc.		
	530	WO 98/08868 A1	03-05-1998	Praecis Pharm., Inc.		
	531	WO 95/08999 A1	04-06-1995	City of Hope		
	532	WO 96/37621 A2	11-28-1996	Morphosys Proteinoptimierung		
CJN	533	AU 707083	07-01-1999	Mouritsen & Elsner AS		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	534	Hock, *et al.* "Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease." *Neuron*. 2003; 38:542-54.	
	535	van Regenmortel, *et al.* "D-peptides as immunogens and diagnostic reagents." *Curr. Opin. Biotech*. 1998; 9(4):377-82.	
	536	Sela, *et al.* "Different roles of D-amino acids in immune phenomena." *FASEB J*. 1999; 11(6):449-56.	
	537	Tjernberg, *et al.* "Controlling amyloid beta-peptide fibril formation with protease-stable ligands." J. Biol Chem. 1997; 272(19):12601-5.	
CJN	538	Flood, *et al.* "Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid B protein." *PNAS*. 1994; 91:380-4.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 21 of 21

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GP	543	5,278,049	01-11-1994	Baker, *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GP	539	Findeis, *et al.* "Modified peptide inhibitors of amyloid B-peptide polymerization." Biochemistry. 1999; 38:6791-6800.	
	540	Benkirane, *et al.* "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues." *The Journal of Biological Chemistry*. 1993; 268(23):26279-85.	
	541	Cribbs, *et al.* "All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All -L-Beta-Amyloids." *J. Biol. Chem.* 1997; 272:7431-6.	
	542	Chishti, *et al.* "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695." *J. Biol.Chem.* 2001; 276(24):21562-70.	
	544	Chothia, *et al.* "Domain Association in Immunoglobulin Molecules." *J. Mol. Biol.* (1985) 186: 651-663	
	545	Wu, *et al.* "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and Their Implications for Antibody Complementarity J Exp Med 1970;132:211-250	
✓	546	Novotny, J. *et al.* "Structural Invariants of Antigen Binding: Comparison of Immunoglobulin V_L-V_H and V_L-V_L domain Dimers." *Proc. Natl. Acad. Sci.* 82:4592-4593 (July 1985)	
GP	547	Frazer, J. K. Capra J.D. "Immunoglobulins: Structure and Function. Paul, W.E., ed. In Fundamental Immunology" 4th ed. Philadelphia, PA: Lippincott-Raven 1999: 37-74	

12/13/04 GP

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/13/04

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	548	Anderson, J.P., *et al.* Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells." *Neurosci Lett.* 1991 Jul 8; 128(1):126-8.	
	549	Anderson, M.W. "Amending the amyloid hypothesis." *The Scientist.* 2004 Oct 25; 18(20).	
	550	Bacskai, B.J., *et al.* "Imaging of amyloid-ß deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy." *Nat Med.* 2001 Mar; 7(3):369-72.	
	551	Bacskai, B.J., *et al.* "Non-Fc-mediated mechanisms are involved in clearance of amyloid-ß in vivo by immunotherapy." *J Neurosci.* 2002 Sep 15; 22(18):7873-8.	
	552	Check, E. "Battle of the mind." *Nature.* 2003 Mar 27; 422(6930):370-2.	
	553	Chromy, B.A., *et al.* "Self-assembly of Aß(1-42) into globular neurotoxins." *Biochemistry.* 2003 Nov 11; 42(44):12749-60.	
	554	Citron, M., *et al.* "Evidence that the 42- and 40-amino acid forms of amyloid-ß protein are generated from the ß-amyloid precursor protein by different protease activities." *Proc Natl Acad Sci USA.* 1996 Nov 12; 93(23):13170-5.	
	555	Citron, M. "Alzheimer's disease: treatments in discovery and development." *Nat Neurosci.* 2002 Nov; 5:1055-7.	
	556	DeMattos, R.B., *et al.* "Brain to plasma amyloid-ß efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease." *Science.* 2002 Mar 22; 295(5563):2264-7.	
	557	DeMattos, R.B., *et al.* "Peripheral anti-Aß antibody alters CNS and plasma Aß clearance and decreases brain Aß burden in a mouse model of Alzheimer's disease." *Proc Natl Acad Sci USA.* 2001 Jul 17; 98(15):8850-5.	
CJN	558	Dodart, J-C., *et al.* "Immunization reverses memory deficits without reducing brain Aß burden in Alzheimer's disease model." *Nat Neurosci.* 2002 May; 5(5):452-7.	

Examiner Signature		Date Considered	1/18/05

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GS	559	Dodel, R.C., *et al.* "Immunotherapy for Alzheimer's disease." *Lancet Neurol.* 2003 Apr; 2(4):215-20.	
	560	Dovey, H.F., *et al.* "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain." *J Neurochem.* 2001 Jan; 76(1):173-81.	
	561	Duff, K., *et al.* "Increased amyloid-ß42(43) in brains of mice expressing mutant presenilin 1." *Nature.* 1996 Oct 24; 383(6602):710-3.	
	562	Eriksen, J.L., *et al.* "NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aß42 in vivo." *J Clin Invest.* 2003 Aug; 112(3):440-9.	
	563	Findeis, M.A. "Approaches to discovery and characterization of inhibitors of amyloid ß-peptide polymerization." *Biochim Biophys Acta.* 2000 Jul 26; 1502(1):76-84.	
	564	Frenkel, D., *et al.* "Reduction of ß-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization." *Vaccine.* 2003 Mar 7; 21(11-12):1060-5.	
	565	Frenkel, D., *et al.* "Towards Alzheimer's ß-amyloid vaccination." *Biologicals.* 2001 Sep-Dec; 29(3-4):243-7.	
	566	Gelinas, D.S., *et al.* "Immunotherapy for Alzheimer's disease." *Proc Natl Acad Sci USA.* 2004 Oct 5; 101 Suppl 2:14657-62.	
	567	Gong, Y., *et al.* "Alzheimer's disease-affected brain: presence of oligomeric Aß ligands (ADDLs) suggests a molecular basis for reversible memory loss." *Proc Natl Acad Sci USA.* 2003 Sep 2; 100(18):10417-22.	
	568	Greenberg, S.M., *et al.* "Alzheimer disease's double-edged vaccine." *Nat Med.* 2003 Apr; 9(4):389-90.	
	569	Haass, C. "New hope for Alzheimer disease vaccine." *Nat Med.* 2002 Nov; 8(11):1195-6.	
	570	Hock, C., *et al.* "Generation of antibodies specific for ß-amyloid by vaccination of patients with Alzheimer disease." *Nat Med.* 2002 Nov; 8(11):1270-5.	
	571	Irizarry, M.C., *et al.* "Alzheimer disease therapeutics." *J Neuropathol Exp Neurol.* 2001 Oct; 60(10):923-8.	
	572	Janus, C., *et al.* "Transgenic mouse models of Alzheimer's disease." *Physiol Behav.* 2001 Aug; 73(5):873-86.	
	573	Klein, W.L., *et al.* "Targeting small Aß oligomers: the solution to an Alzheimer's disease conundrum?" *Trends Neurosci.* 2001 Apr; 24(4):219-24.	
	574	Mattson, M.P., *et al.* "Good and bad amyloid antibodies." *Science.* 2003 Sep 26; 301(5641):1847-9.	
	575	McLaurin, J., *et al.* "Therapeutically effective antibodies against amyloid- ß peptide target amyloid-ß residues 4-10 and inhibit cytotoxicity and fibrillogenesis." *Nat Med.* 2002 Nov; 8(11):1263-9. Epub 2002 Oct 15.	
	576	Monsonego, A., *et al.* "Increased T cell reactivity to amyloid ß protein in older humans and patients with Alzheimer disease." *J Clin Invest.* 2003 Aug; 112(3):415-22.	
GS	577	Monsonego, A., *et al.* "Immunotherapeutic approaches to Alzheimer's disease." *Science.* 2003 Oct 31; 302(5646):834-8.	

Examiner Signature		Date Considered	11/18/05

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	ELN-002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	578	Paganetti, P.A., *et al.* "Amyloid precursor protein truncated at any of the γ-secretase sites is not cleaved to ß -amyloid." *J Neurosci Res.* 1996 Nov 1; 46(3):283-93.	
	579	Pallitto, M.M., *et al.* "Recognition sequence design for peptidyl modulators of ß-amyloid aggregation and toxicity." *Biochemistry.* 1999 Mar 23; 38(12):3570-8.	
	580	Pfeifer, M., *et al.* "Cerebral hemorrhage after passive anti-Aß immunotherapy." *Science.* 2002 Nov 15; 298(5597):1379.	
	581	Schmid, R.E. "Study suggests Alzheimer vaccine fix." www.msnbc.com/news. 2002; 1-5.	
	582	Selkoe, D.J. "Alzheimer's disease is a synaptic failure." *Science.* 2002 Oct 25; 298(5594): 789-91.	
	583	Sigurdsson, E.M., *et al.* "Immunization with a nontoxic/nonfibrillar amyloid-ß homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice." *Am J Pathol.* 2001 Aug; 159(2):439-47.	
	584	Solomon, B., *et al.* "Generation and brain delivery of anti-aggregating antibodies against ß-amyloid plaques using phage display technology." *J Neural Transm Suppl.* 2002; (62):321-5.	
	585	Solomon, B. "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease." *DNA Cell Biol.* 2001 Nov; 20(11):697-703.	
	586	White, A.R., *et al.* "Immunotherapy as a therapeutic treatment for neurodegenerative disorders." *J Neurochem.* 2003 Nov; 87(4):801-8.	
	587	Nicoll, J.A., *et al.* "Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report." *Nat Med.* 2003 Apr; 9(4):448-52.	
	588	Pan, W., *et al.* "Antibodies to ß-amyloid decrease the blood-to-brain transfer of ß-amyloid peptide." *Exp Biol Med* (Maywood). 2002 Sep; 227(8):609-15.	
	589	Sergeant, N., *et al.* "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach." *J Neurochem.* 2003 Jun; 85(6):1581-91.	
	590	Walsh, D.M., *et al.* "Naturally secreted oligomers of amyloid ß protein potently inhibit hippocampal long-term potentiation in vivo." *Nature.* 2002 Apr 4; 416(6880):535-9.	
	591	Washington University in St. Louis School of Medicine. "Study Gives Clues to Working of Anti-Alzheimer Antibody." Retrieved from internet www.medicine.wustl.edu/~wumpa/news, December 15, 2004.	
CJN	592	"Researchers Devlop Blood Test to Diagnose Alzheimer's-Type Changes in Mice." Retrieved from internet www.businesswire.com, December 15, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	1/18/05